All In MedTech

Device Trial Radar · NCT00593528

PTFE Covered Stents Versus Naked Stents in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)

Randomized Study With Medico-economic Evaluation Comparing the Use of PTFE Covered Stents vs Naked Stent in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

138

Actual

Start

Feb 18, 2008

Primary completion

Jul 11, 2011

Study completion Jul 11, 2011

Sponsor

Lead sponsor
University Hospital, ToursAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 15, 2008

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transjugular intrahepatic portosystemic shunts (TIPS) have been increasingly used for the treatment of complications of portal hypertension in patients with cirrhosis. The initial experiment of the TIPS was reported during the 1990s with stents of various brands, manufacture and sizes, but all "non covered", thus owing the pseudointimal hyperplasia growing inside the stent, which progressively decreases the diameter of the shunt and thus its efficacy. Since the beginning of the 2000s, appeared stents known as "covered" by polytetrafluoroethylene (PTFE) designed to reduce the obstruction rate and thus the frequency shunt revisions. However, these stents are, on average, 2.5 times more expensive than the non covered stents and the cost-effectiveness ratio of the TIPS according to the type of stents used has not been assessed. The aim of this multicentric and randomized study is to assess the cost-effectiveness ratio of these 2 principles of TIPS, the one using stents covered by PTFE, relatively expensive but seldom becoming obstructed, and the other using non covered stents, less expensive than PTFE but requiring regular gestures of redilatation. Population concerned: Patients with a cirrhotic portal hypertension responsible for: * recurrent variceal bleeding * refractory ascite (or hydrothorax)

Conditions

  • Cirrhotic Portal Hypertension

Interventions

  • Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)Device

    Vascular Stents

  • PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)Device

    Vascular Stents

  • Transjugular intrahepatic portosystemic shunt (TIPS)Procedure

    Transjugular intrahepatic portosystemic shunt (TIPS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TIPS permeability rateTime frame: one year
  2. Cost of the TIPS and patient care according to the type of stent used brought back to an indicator of effectivenessTime frame: one year

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Chru Bordeaux

    Bordeaux, France

  • Chru Caen

    Caen, France

  • Chru Clermont Ferrand

    Clermont-Ferrand, France

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.